Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Boule Diagnostics: Earnings beat on adj. EBIT in Q4 - ABG

Boule Diagnostics

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Underlying earnings better than expected
4.2% organic sales growth in Q4
Near-term uncertainty persists, but long-term potential unchanged


Q4 negatively impacted by one-offs

Boule Diagnostics delivered another quarter with positive organic growth in Q4, and adj. EBIT (excluding non-recurring items) of SEK 15.1m was 19% better than what we had expected (ABGSCe was SEK 12.6m). The earnings beat In Q4 was to a large degree due to higher gross margin (44.5% vs ABGSCe of 42.0%). Cash flow generation was strong in Q4 with OCF of SEK 29.2m, equal to a cash conversion (OCF/EBITDA) of 142%, helped by improved net working capital in Q4. However, Boule Diagnostics continues to re-invest a large part of its OCF in R&D (capitalised) in its new 5-part system, which is scheduled to be launched later in 2024.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.